(Q36993067)

17 August 2017

1 reference

8 December 2020

1 reference

PubMed publication ID

27196461

title

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature (English)

1 reference

non-small-cell lung carcinoma

17 August 2017

1 reference

14 September 2020

1 reference

8 December 2020

1 reference

14 September 2020

1 reference

8 December 2020

Lin Ding

1

1 reference

17 August 2017

Qing-Jian Li

2

1 reference

17 August 2017

Kai-Yun You

3

1 reference

17 August 2017

Zhi-Min Jiang

4

1 reference

17 August 2017

He-Rui Yao

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 May 2016

4 references

17 August 2017

3 April 2019

14 September 2020

8 December 2020

4 references

17 August 2017

3 April 2019

14 September 2020

8 December 2020

95

1 reference

17 August 2017

20

1 reference

17 August 2017

e3598

1 reference

Creative Commons Attribution 4.0 International

17 August 2017

3 references

3 April 2019

14 September 2020

on focus list of Wikimedia project

8 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: An adverse health effect from exposure to smoking

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Clinical advances in the development of novel VEGFR2 inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Angiogenesis in cancer, vascular, rheumatoid and other disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4902403

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

4 September 2018

1 reference

12 December 2020

Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma

1 reference

12 December 2020

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial

1 reference

12 December 2020

Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer

1 reference

12 December 2020

10.1097/MD.0000000000003598

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

27196461

1 reference